Drug Profile
Research programme: biosimilars - Bionovis
Alternative Names: BNV-003; BNV-004Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Bionovis
- Class
- Mechanism of Action Epidermal growth factor receptor antagonists; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer; Head and neck cancer; Multiple sclerosis
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for preclinical development in Colorectal-cancer in Brazil
- 28 Jul 2019 No recent reports of development identified for preclinical development in Head-and-neck-cancer in Brazil
- 28 Jul 2019 No recent reports of development identified for preclinical development in Multiple-sclerosis in Brazil